evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract
5657,GENE_BACKGROUND,,"BCL2 (B-cell lymphoma 2) is a key regulator of cell apoptosis, and is part of the BCL2 family of proteins that orchestrate the intrinsic apoptotic pathway (PMID: 24355989). BCL2 is considered a pro-survival factor that inhibits BAX-mediated mitochondrial permeability, thus preventing cytochrome c release and downstream caspase 9 activation through APAF1 (PMID: 9390557, 9219694, 9390557). BCL2 is commonly linked to the immunoglobulin (Ig) heavy chain locus in follicular B-cell lymphomas via the t(14;18) chromosomal translocation (PMID:2875799). This results in robust expression of BCL2 and downstream pro-survival signals, a key step in lymphomagenesis (PMID:7632929). Progression of follicular lymphoma to a more aggressive disease state is often associated with MYC translocation, suggesting a synergy between BCL2 and MYC in cancer progression (PMID:1638027, 12015982). BCL2 is found to be translocated and overexpressed particularly in haematological malignancies, but is infrequently mutated (PMID: 3262202, 16193090). Venetoclax is a small molecule inhibitor of BCL2, and has been approved for treatment in patients with relapsed chronic lymphocytic leukemia (CLL) harboring a specific genetic alteration (PMID: 26639348).",,2017-10-18,,596,BCL2,"BCL2, apoptosis regulator",True,ENST00000333681,NM_000633.2,Bcl-2,PPP1R50,False,12015982,Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.,Cell,2018-05-03T20:02:00,109,3,321-34,Pelengaris S et al,,,0001-05-03,,16193090,Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas.,Leukemia,2017-12-01T20:05:00,19,12,2313-23,Galteland E et al,,,0001-12-01,,7632929,Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice.,Blood,0001-08-15,86,4,1255-60,Linette GP et al,,,0001-08-15,,24355989,Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.,Nature reviews. Molecular cell biology,2018-01-01T20:14:00,15,True,49-63,Czabotar PE et al,doi: 10.1038/nrm3722,,0001-01-01,,9219694,Inhibition of Bax channel-forming activity by Bcl-2.,"Science (New York, N.Y.)",0001-07-18,277,5324,370-2,Antonsson B et al,,,0001-07-18,,2875799,Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.,Cell,0001-10-10,47,True,19-28,Cleary ML et al,,,0001-10-10,,3262202,Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.,Nature,0001-09-29,335,6189,440-2,Vaux DL et al,,,0001-09-29,,26639348,Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.,The New England journal of medicine,2018-01-28T20:16:00,374,4,311-22,Roberts AW et al,doi: 10.1056/NEJMoa1513257,,0001-01-28,,9390557,Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade.,Cell,0001-11-14,91,4,479-89,Li P et al,,,0001-11-14,,1638027,MYC rearrangements in histologically progressed follicular lymphomas.,Blood,0001-08-01,80,3,758-67,Yano T et al,,,0001-08-01,
5656,GENE_SUMMARY,,"BCL2, an anti-apoptotic protein, is frequently altered in non-Hodgkin lymphoma.",,2017-10-23,,596,BCL2,"BCL2, apoptosis regulator",True,ENST00000333681,NM_000633.2,Bcl-2,PPP1R50,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
